Rezolute, Inc. Share Price & Technical Analysis
RZLT · $3.25 (-2.69%)
Healthcare / Biotechnology
$3.25
-2.69%
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
0% return in May, 22% avg return in past 3 year May month.
34% return in 2026, 43% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 38% | -3% | 0% | 0% | 0% | – | – | – | – | – | – | – | 34% |
| 25 | 6% | -14% | -34% | 31% | 8% | 7% | 31% | 22% | 32% | -1% | 4% | -75% | 19% |
| 24 | 10% | 45% | 56% | 0% | 54% | 8% | 2% | 4% | 0% | 15% | -9% | -4% | 181% |
| 23 | 30% | -4% | -30% | 0% | 5% | -9% | -5% | -26% | -7% | -31% | -20% | 25% | -72% |
| 22 | -4% | -43% | 31% | 15% | -26% | 7% | -9% | -23% | 17% | -32% | -11% | 24% | -55% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$314.37M
P/E ratio
—
52W high
$11.46
52W low
$1.07
Volume
8,14,434
Beta
0.67
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Rezolute, Inc. share price today?
- Rezolute, Inc. (RZLT) last traded around $3.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RZLT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RZLT. Download the app for real-time alerts.
- How can I analyze Rezolute, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.